Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Taltz ® (ixekizumab) injektion
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
The US Taltz package insert states that if a dose is missed, the dose should be administered as soon as possible. Thereafter, resume dosing at the regular scheduled time.1
In the ixekizumab clinical development program, ixekizumab was administered at approximately the same time each day, as much as possible.2,3
For the pivotal UNCOVER adult psoriasis clinical trials, injections not administered on the scheduled day were to be administered
within 1 to 3 days of the scheduled day during the induction period (week 0-12), and
within 5 days of the scheduled day after week 12.2
Therapeutic Indication
Ixekizumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.4
1. Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.
2. Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345-356. http://dx.doi.org/10.1056/NEJMoa1512711
3. Data on file, Eli Lilly and Company and/or one of its subsidiaries.
4. Taltz [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Datum fӧr senaste ӧversyn 2019 M02 12